Trematode Infections of Man

  • William C. Campbell
  • Edito G. Garcia


A consideration of the chemotherapy of trematode infections of man will invariably be unevenly distributed with respect to the parasites involved. The great preponderance of attention must be devoted to the blood flukes or schistosomes, because of their great medical importance and because so much is known about their treatment. The remaining flukes, having various degrees of medical importance and having a lesser body of therapeutic lore, can be covered more briefly.


Schistosoma Mansoni Schistosoma Haematobium Trematode Infection Schistosomiasis Japonica Schistosome Species 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ambroise-Thomas P. Goullier A. and Peyron F. 1984 Therapeutic results in opisthorchiasis with praziquantel in a reinfection-free environment in France Arzneimittelforsch. 34 II): 1177–117PubMedGoogle Scholar
  2. Abaza, H. H., Hammouda, N., Abd Rabbo, H., and Shafei, A. Z., 1978, Chemotherapy of schistosomal colonic polyposis with oxamniquine, Trans. R. Soc. Trop. Med. Hyg. 72:602–604.PubMedCrossRefGoogle Scholar
  3. Bennett, J. K., and Depenbusch, J. W., 1984, The chemotherapy of schistosomiasis, in: Parasitic Diseases, Vol. 2: The Chemotherapy (J. M. Mansfield, ed.), pp. 73–131, Dekker, New York.Google Scholar
  4. Bunnag, D., Pungpark, S., Harinasuta, T., Viravan, C., Vanijanonta, S., Suntharasamai, P., Migasena, S., Charoenlarp, P., Riganti, M., and LooAreesuwan, S., 1984, Opisthorchis viverrini: Clinical experience with praziquantel in hospital for tropical diseases, Arzneimittelforsch. 34(11): 1173–1174.PubMedGoogle Scholar
  5. Campbell, W. C., and Cuckler, A. C., 1961, The prophylactic effect of topically applied cedarwood oil on infection with Schistosoma mansoni in mice, Am. J. Trop. Med. Hyg. 10:712–715.PubMedGoogle Scholar
  6. Campbell, W. C., and Cuckler, A. C., 1967, Inhibition of egg production of Schistosoma mansoni in mice treated with nicarbazin, J. Parasitol. 53:977–980.PubMedCrossRefGoogle Scholar
  7. Campbell, W. C., and Rogers, E. F., 1971, Effect of nitrocarbanilides on Schistosoma mansoni, J. Parasitol. 57:1372–1373.PubMedCrossRefGoogle Scholar
  8. Campbell, W. C, Bartels, E., and Cuckler, A. C, 1978, A method for detecting chemotherapeutic activity against Schistosoma mansoni in mice, J. Parasitol. 64:69–77.PubMedCrossRefGoogle Scholar
  9. Cao, W. J., He, L. Y., Zhong, H. L. Chung, H. L., Xu, Z. S., Bi, Y. C., Yu, G. T., Zhang, Q. C., Li, K. C., Yang, E. V., She, G., and Li, H. J., 1984, Paragonimiasis: Treatment with praziquantel in 40 human cases and in 1 cat, Arzneimittelforsch. 34(II): 1203–1204.PubMedGoogle Scholar
  10. Chen, C. Y., and Hsieh, W. C., 1984, Clonorchis sinensis: Epidemiology in Taiwan and clinical experience with praziquantel, Arzneimittelforsch. 34(II): 1160–1162.PubMedGoogle Scholar
  11. Chen, M. G., Hua, X. J., Wan, Z. R., Weng, Y. Q., Wang, M. J., Zhu, P. J., He, B. Z., and Xu, M. Y., 1983, Praziquantel in 237 cases of clonorchiasis sinensis, Chin. Med. J. 96:935–940 (English transi.).PubMedGoogle Scholar
  12. Cho, S. Y., Kang, S. Y., and Lee, J. B., 1984, Metagonimiasis in Korea, Arzneimittelforsch. 34(II): 1211–1213.PubMedGoogle Scholar
  13. Davis, A., 1982, Manage of the patient in schistosomiasis, in: Schistosomiasis (P. Jordan and G. Webbe, eds.), pp. 184–226, Heineman Medical Books, London.Google Scholar
  14. Davis, A., and Bailey, D. R., 1969, Metrifonate in urinary schistosomiasis, Bull. WHO 41:209–224.PubMedGoogle Scholar
  15. Davis, A., and Wegner, D. H. G., 1979, Multicenter trials of praziquantel in the treatment of human schistosomiasis: Designs and techniques, Bull. WHO 51:767–772.Google Scholar
  16. Davis, A., Biles, J. E., and Wrich, A. M., 1979, Initial experience with praziquantel in the treatment of human infection due to Schistosoma haematobium, Bull. WHO 57:773–780.PubMedGoogle Scholar
  17. Delolme, H., Cot, M., Cavallo, A., Kouka-Bemba, D., and Sentilhes, L., 1983, Réflexions sur le traitement de masse des bilharzioses à Schistosoma haematobium dans les états membres de l’Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Bull. Soc. Pathol. Exot Fil. 76:534–541.Google Scholar
  18. de Souza Dias, L. C. S., Pedro, R. V., and Deberaldini, E. R., 1982, Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: Resistance of Schistosoma mansoni to schistosomicidal agents, Trans. R. Soc. Trop. Med. Hyg. 76:652–659.PubMedCrossRefGoogle Scholar
  19. Dhiensiri, T., Eua-Ananta, Y., Bunnag, D., Harinasuta, T., and Schelp, P. F., 1984, Roentgenographically controlled healing of gallbladder lesions in opisthorchiasis after praziquantel treatment, Arzneimittelforsch. 34(II):1175–1177.PubMedGoogle Scholar
  20. Doehring, E., Feldmeier, H., Dafalla, A. A., Ehrich, J. H., Vester, U., and Poggensee, U., 1984, Intermittent chemotherapy with trichlorfon (metrifonate) reverses proteinuria, hematuria, and leukocyturia in urinary schistosomiasis: Results of a three–year field study, J. Infect. Dis. 149:615–620.PubMedCrossRefGoogle Scholar
  21. Feldmeier, H., Doehring, E., Daffala, A. A., Omer, A. H. S., and Dietrich, M., 1981, Efficacy of metrifonate in urinary schistosomiasis in light and heavy infections, Tropenmed. Parasitol. 33:102–106.Google Scholar
  22. Feldmeier, H., Doehring, E., Daffala, A. A., Omer, A. H. S., and Dietrich, M., 1982, Efficacy of metrifonate in urinary schistosomiasis: Comparison of reduction of Schistosoma haematobium and S. mansoni eggs, Am.J. Trop. Med. Hyg. 31:1188–1194.PubMedGoogle Scholar
  23. Foster, R., and Cheetham, B. L., 1973, Studies with the schistosomicide oxamniquine (UK4271) I, Trans. R. Soc. Trop. Med. Hyg. 67:674–684.PubMedCrossRefGoogle Scholar
  24. Friedheim, E. A. H., 1973, Chemotherapy of schistosomiasis, in: Chemotherapy of Helminthiasis (R. Cavier and F. Hawking, eds.), pp. 29–144, Pergamon Press, Oxford.Google Scholar
  25. Frohberg, H., 1984, Results of toxicological studies on praziquantel, Arzneimittelforsch. 34(11): 1137–1144.PubMedGoogle Scholar
  26. Fu, S., Zhou, X. Z., and Fan, Y., 1983, Comparative study on different dose schedules of praziquantel in the treatment of schistosomiasis japonica, J. Parasitol. Parasitic Dis. 1:32–36.Google Scholar
  27. Gilbert, B., DeSouza, J. P., Fortes, C. C, DosSantos, F., DoPrado Seabra, A., Kitagawa, M., and Pellegrino, J., 1970, Chemoprophylactic agents in schistosomiasis: Active and inactive terpenes, J. Parasitol. 56:397–398.PubMedCrossRefGoogle Scholar
  28. Gonnert, R., and Andrews, P., 1977, Praziquantel, a new broad-spectrum antischistosomal agent, Z. Parasitenk. 52:129–150.PubMedCrossRefGoogle Scholar
  29. Greene, L. K., Grenan, M. M., Davidson, D. E., Jr., Jones, D. H., and Shedd, T. R., 1983, Amoscanateas a topically applied chemical for prophylaxis against Schistosoma mansoni infections in mice, Am. J. Trop. Med. Hyg. 32:1356–1363.PubMedGoogle Scholar
  30. Harinasuta, T., Bunnag, D., and Radomyos, P., 1984, Efficacy of praziquantel on fasciolopsiasis, Arzneimittelforsch. 34(II):1214–1215.Google Scholar
  31. Horstmann, R. D., Feldheim, W., Feldmeier, H., and Dietrich, M., 1981, High efficacy of praziquantel in the treatment of 22 patients with Clonorchis/Opisthorchis infections, Tropenmed. Parasitol. 32:157–160.PubMedGoogle Scholar
  32. Ishizaki, T., Kamo, E., and Boelone, E., 1979, Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infection, Bull. WHO 57:787–792.PubMedGoogle Scholar
  33. Islip, P. J., 1973, Progress in the experimental chemotherapy of helminth infections, Fortschr. Arzneimittelforsch. 17:241–319.Google Scholar
  34. Jackson, H., Davies, P., and Bock, M., 1968, Chemosterilization of Schistosoma mansoni, Nature (Lond.) 218:977.CrossRefGoogle Scholar
  35. James, C., Webbe, G., and Nelson, G. S., 1977, The susceptibility to praziquantel of Schistosoma haematobium in the baboon (Papio anubis) and of S. japonicum in the vervet monkey (Cercopithecus aethiops), Z. Parasitenk. 52:1179–1194.CrossRefGoogle Scholar
  36. Johnson, R. J., Dunning, S. B., Minshew, B. H., and Jong, E. C., 1983, Successful praziquantel treatment of paragonimiasis following bithionol failure, Am.J. Trop. Med. Hyg. 32:1309–1311.PubMedGoogle Scholar
  37. Katz, N., and Pellegrino, J., 1974, Experimental chemotherapy of schistosomiasis mansoni, Adv. Parasitol. 12:369–390.PubMedCrossRefGoogle Scholar
  38. Katz, N., Zicker, F., and Pereira, J. P., 1977, Field trials with oxaminiquine in schistosomiasis mansoniendemic area, Am. J. Trop. Med. Hyg. 26:234–237.PubMedGoogle Scholar
  39. Katz, N., Rocha, R. S., and Chaves, A., 1979, Preliminary trials with praziquantel in human infections due to Schistosoma mansoni, Bull. WHO 57:781–786.PubMedGoogle Scholar
  40. Katz, N., Rocha, R. S., and Chaves, A., 1981, Clinical trials with praziquantel in Schistosoma mansoni, Rev. Inst. Med. Trop. Sao Paulo 23:72–78.PubMedGoogle Scholar
  41. Kern, P., Burchard, G. D., and Deitrich, M., 1984, Comparative study of oltipraz versus praziquantel for treatment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and S. haematobium), Tropenmed. Parasitol. 35:95–99.PubMedGoogle Scholar
  42. Kilpatrick, M. E., El Masry, N. A., Bassily, S., and Farid, Z., 1982, Oxamniquine versus niridazole for treatment of uncomplicated Schistosoma mansoni infection, Am. J. Trop. Med. Hyg. 31:1164–1167.PubMedGoogle Scholar
  43. Krajden, S., Keystone, J. S., and Glenn, C., 1983, Safety and toxicity of oxamniquine in the treatment of Schistosoma mansoni infections, with particular reference to electroencephalographic abnormalities, Am.J. Trop. Med. Hyg. 32:1344–1346.PubMedGoogle Scholar
  44. Kuang, Q. H., Zhou, Y. T., Lei, S. Z., Cao, W. J., and Zhong, H. L. Chung, H. L., 1984, Clonorchiasis: Treatment with Praziquantel in 50 cases, Arzneimittelforsch. 34:(II): 1162–1163.PubMedGoogle Scholar
  45. Lambertucci, J. R., Greco, D. B., Pedroso, E. R. P., Rocha, M. O. D., Salazar, H-M, and DeLima, D. P., 1982, A double blind trial with oxamniquine in chronic schistosomiasis mansoni, Trans. R. Soc. Trop. Med. Hyg. 76:751–755.PubMedCrossRefGoogle Scholar
  46. Lammler, G., 1968, Chemotherapy of trematode infections, in: Advances in Chemotherapy (A. Goldin, F. Hawking, and R. J. Schnitzer, eds.), pp. 153–251, Academic Press, New York.Google Scholar
  47. Lapierre, J., Keita, A., Faurant, C., Heyer, F., Tourte-Schaefer, C., Ancelle, T., and Dupouy-Camet, J., 1983, Treatment of 700 cases of bilharziasis with the new drugs oxamniquine, oltipraz, praziquantel, Bull. Soc. Pathol. Exot. Fil. 76:526–533.Google Scholar
  48. Le, W. J., You, J. Q., and Mei, J. Y., 1983, Chemotherapeutic effect of artesunate in experimental schistosomiasis, Yao Hsueh Hsueh Pao 18:619–621.PubMedGoogle Scholar
  49. Lee, S. H., 1984, Large scale treatment of Clonorchis sinensis infections with praziquantel under field conditions, Arzneimittelforsch. 34(11): 1227–1230.PubMedGoogle Scholar
  50. Legator, M. S., Connor, T. H., and Stoeckel, M., 1975, Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice, Science 188:1118–1119.PubMedCrossRefGoogle Scholar
  51. Mahmoud, A. A. F., Siongok, T. K. A., Ouma, J., Houser, H. B., and Warren, K. S., 1983, Effect of targeted mass treatment on intensity of infection and morbidity in schistosomiasis mansoni, Lancet 1:849–851.PubMedCrossRefGoogle Scholar
  52. Mason, P. R., and Tswana, S. A., 1984, Single-dose metrifonate for the treatment of Schistosoma haematobium infection in an endemic area of Zimbabwe, Am. J. Trop. Med. Hyg. 33:599–601.PubMedGoogle Scholar
  53. McMahon, J. E., 1976, Oxamniquine (UK4271) in Schistosoma haematobium infections, Ann. Trop. Med. Parasitol. 70:121–122.PubMedGoogle Scholar
  54. McMahon, J. E., 1983, A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium, Am. Trop. Med. Parasitol. 77:139–142.Google Scholar
  55. Minggang, C., Sui, F., Xiangjin, H., and Huimin, W., 1984, A retrospective survey on side effects of praziquantel among 25693 cases of schistosomiasis japonica, Southeast Asian J. Trop. Med. Publ. Health 14:495–500.Google Scholar
  56. Monson, M. H., Koenig, J. W., and Sachs, R., 1983, Successful treatment with praziquantel of six patients infected with the African lung fluke, Paragonimus uterobilateralis, Am.J. Trop. Med. Hyg. 32:371–375.PubMedGoogle Scholar
  57. Muftic, M., 1970, New methods for testing schistosomicidal drugs, J. Trop. Med. Hyg. 73:232–234.PubMedGoogle Scholar
  58. Nash, T. E., Hofstetter, M., Cheeves, A. W., and Ottesen, E. A., 1982, Treatment of Schistosoma mekongi with praziquantel: A double-blind study, Am. J. Trop. Med. Hyg. 31:977–982.PubMedGoogle Scholar
  59. Omer, A. H. S., and Teesdale, C. H., 1978, Metrifonate trial in the treatment of various presentations of Schistosoma haematobium and Schistosoma mansoni infections in the Sudan, Ann. Trop. Med. Parasitol. 12:145–150.Google Scholar
  60. Pellegrino, J., and Katz, N., 1968, Experimental chemotherapy of schistosomiasis mansoni, Adv. Parasitol. 6:233–290.PubMedCrossRefGoogle Scholar
  61. Pellegrino, J., and Katz, N., 1969, Experimental chemotherapy of schistosomiasis, part 4: oogram studies with nicarbazin, ang suppressive agent, Rev. Inst. Med. Trop. Sao Paulo 11:215–221.PubMedGoogle Scholar
  62. Pellegrino, J., Lima-Costa, F. F., Carlos, M. A., and Mello, R. T., 1977, Experimental chemotherapy of schistosomiasis mansoni XIII, Z. Parasitenk. 52:151–168.PubMedCrossRefGoogle Scholar
  63. Pieron, R., Mafart, Y., Lesobre, B., Grivaux, M., and Lancastre, F., 1984, L’oltipraz en traitement bref de la schistosomose à S. haematobium. Trois prises en un jour ou une seule prise, Therapie 39:167–176.PubMedGoogle Scholar
  64. Pitchford, R. J., and Lewis, A. M., 1978, Oxamniquine in the treatment of various schistosome infections in South Africa, South Afr. Med. J. 53:677–680.Google Scholar
  65. Plestina, R., Davis, A., and Bailey, D. R., 1972, Effect of metrifonate on blood cholinesterases in children during the treatment of schistosomiasis, Bull. WHO 46:747–759Google Scholar
  66. Pugh, R. N., and Teesdale, C. H., 1984, Long-term efficacy of single-dose oral treatment in schistosomiasis haematobium, Trans. R. Soc. Trop. Med. Hyg. 78:55–59.PubMedCrossRefGoogle Scholar
  67. Radomyos, P., Bunnag, D., and Harinasuta, T., 1982, Echinostoma ilocanum infection in man in Thailand, Southeast Asian J. Trop. Med. Publ. Health 13:265–269.Google Scholar
  68. Rim, H. J., 1973, Chemotherapy of trematode infection excluding schistosomiasis, in: Proceedings of the Tenth SEAMEO-TROPMED Seminar: Symposium on Chemotherapy in Tropical Medicine of Southeast Asia and the Far East, October 26–30, 1972, Bangkok.Google Scholar
  69. Rim, H. J., and Chang, Y. S., 1980, Chemotherapeutic effect of niclofolan and praziquantel in the treatment of paragonimiasis, Korea Univ. Med. J. 17:113–126.Google Scholar
  70. Rim, H. J., Lyu, K. S., Lee, J. S., and Koo, K. H., 1981, Clinical evaluation of therapeutic effect of praziquantel (Embay 8440) against Clonorchis sinensis infection, Ann. Trop. Med. Parasitol. 15:27.Google Scholar
  71. Rim, H. J., 1984, Paragonimiasis: Experimental and clinical experience with praziquantel in Korea, Arzneimittelforsch. 34(11): 1197–1203.PubMedGoogle Scholar
  72. Ruenwongsa, P., and Thamavit, W., 1983, Increased efficacy of liposomes-Encapsulated praziquantel in treatment of opisthorchiasis in hamsters, Southeast Asian J. Trop. Med. Publ. Health 14:501–504.Google Scholar
  73. Saif, M., Koura, M., and Abdel-Fattah, F., 1973, The oral treatment of 5. haematobium infection with metrifonate, J. Egypt. Med. Assoc. 56:527–531.Google Scholar
  74. Santos, A. T., Blas, B. L., Nosenas, J. S., Portillo, G. P., Ortega, D. M., Hayashi, M., and Boehme, K., 1979, Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines, Bull. WHO 57:593–900.Google Scholar
  75. Santos, A. T., Blas, B. L., Portillo, G. P., Nosenas, J. S., Poliquit, O., and Papasin, M., 1984, Phase III clinical trials with praziquantel in S. japonicum infections in the Philippines, Arzneimittelforsch. 34(II):1221–1223.PubMedGoogle Scholar
  76. Sleigh, A. C., Mott, K. E., and Franca Silva, J. T., 1981, A three–year follow-up of chemotherapy with oxamniquine in a Brazilian community with endemic schistosomiasis, Trans. R. Soc. Trop. Hyg. 75:234–238.CrossRefGoogle Scholar
  77. Soh, C. T., 1984, Clonorchis sinensis: Experimental and clinical studies with praziquantel in Korea, Arzneimittelforsch. 34(II): 1156–1159.PubMedGoogle Scholar
  78. Sornmani, S., Schelp, F. P., Vivatanasesth, P., Patihatakorn, W., Impand, P., Sitabutra, P., Worasan, P., and Preuksaraj, S., 1984, A pilot project for controlling O. viverrini infection in Nong Wai, Northeast Thailand, by applying praziquantel and other measures, Arzneimittelforsch. 34(11): 1231–1234.PubMedGoogle Scholar
  79. Spitalny, K. C., Senft, A. W., Meglio, F. D., Morgan, J., and Peter, G., 1982, Treatment of pulmonary paragonimiasis with a new broad-spectrum anthelmintic, praziquantel, J. Pediatr. 101:144–146.PubMedCrossRefGoogle Scholar
  80. Standen, O. D., 1963, Chemotherapy of helminthic infections, in: Experimental Chemotherapy (R. J. Schnitzer and F. Hawking, eds.), Vol. 1, pp. 701–892, Academic Press, New York and London.Google Scholar
  81. Supanvanich, S., Supavonich, K., and Pawabut, P., 1981, Field trial of praziquantel in human opisthorchiasis in Thailand, Southeast Asian J. Trop. Med. Publ. Health 12:598–602.Google Scholar
  82. Vanijanonta, S., Bunnag, D., and Harinasuta, T., 1984, Paragonimus heterotremus and other Paragonimus spp. in Thailand: Pathogenesis, clinic and treatment, Arzneimittelforsch. 34(11): 1186–1188.PubMedGoogle Scholar
  83. Warren, K. S., 1970, Suppression of hepatosplenic schistosomiasis mansoni in mice by nicarbazin, a drug that inhibits egg production by schistosomes, J. Infect. Dis. 121:514–521.PubMedCrossRefGoogle Scholar
  84. Warren, K. S., and Mahmoud, A. A. F., 1976, Targeted mass treatment. A new approach to the control of schistosomiasis, Trans. Assoc. Am. Physicians 89:195–204.PubMedGoogle Scholar
  85. Webbe, G., and James, C., 1977, A comparison of the susceptibility of praziquantel of Schistosomahaematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters, Z. Parasitenk. 52:169–177.PubMedCrossRefGoogle Scholar
  86. Webbe, G., and Jordan, P., 1982, Control, in: Schistosomiasis (P. Jordan and G. Webbe, eds.), pp. 293–349, Heinemann Medical Books, London.Google Scholar
  87. Wegner, D. H. G., 1984, The profile of the trematodicidal compound praziquantel, Arzneimittelforsch. 34(11): 1132–1136.PubMedGoogle Scholar
  88. Wykoff, D. E., 1958, Studies on Clonorchis sinensis. III, J. Parasitol. 44:461–466.PubMedCrossRefGoogle Scholar
  89. Yokogawa, M., 1984, Experimental chemotherapy of paragonimiasis, Arzneimittelforsch. 34(11): 1193–1196.PubMedGoogle Scholar
  90. Yoshida, Y., Miyaké, T., Nakaniski, Y., Nishido, K., Yamanashi, Y., Ishikawa, T., Fujisoka, K., Tanaka, A., and Embara, S., 1962, Cases of human infection with Fasciola sp. and treatment with Bithionol, Jpn.J. Parasitol. 11:41–43.Google Scholar
  91. Zhou, G. X., 1983, Clinical observation on schistosomiasis japonica treated with amoscanate and phenithionate in a hyperendemic area, Chung Hua Nei Ko Tsa Chih 22:634–645PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • William C. Campbell
    • 1
  • Edito G. Garcia
    • 2
  1. 1.Merck Institute for Therapeutic ResearchRahwayUSA
  2. 2.Department of Parasitology, Institute of Public HealthUniversity of the PhilippinesErmita, ManilaPhilippines

Personalised recommendations